Optimality, Future and Terminal Costs: Comment on “Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran”

Noga Gershon, Yakir Berchenko

Research output: Contribution to journalLetterpeer-review

Original languageEnglish
Pages (from-to)383-384
Number of pages2
JournalPharmacoEconomics
Volume36
Issue number3
DOIs
StatePublished - 1 Mar 2018

ASJC Scopus subject areas

  • Pharmacology
  • Health Policy
  • Public Health, Environmental and Occupational Health

Cite this